Futura Medical PLC (AIM:FUM, OTC:FAMDF) earlier this week caught the market a little off guard as it shared revenue guidance for the first time as sales of its breakthrough erectile dysfunction gel start to build.
According to research conducted by UK brokerage firm Liberum Capital, Futura has stated that it was "highly encouraged" by Eroxon's early progress, with initial orders and market demand matching expectations.
Consequently, the company has guided for sales of at least £1.5mln in the first half of the fiscal year 2023.
Previously, revenue was not included in forecasts due to difficulties in predicting the volume and timing of stocking orders.
However, considering the success of Eroxon's launch, a full-year revenue of £3mln is now predicted.
"We view this statement as further evidence that Futura is maturing into a revenue-generating and, ultimately, a profitable company," Liberum's analysts said in a report.
This optimism is buoyed by a successful warrant exercise conducted last week that resolved any remaining concerns about the firm's financial health.
Futura's balance sheet is now expected to close the year with over £5mln in cash, thanks to the exercise of warrants and an additional milestone payment of £250,000.
Liberum's research indicates that the company is adequately funded until the end of 2025, which removes lingering concerns around the balance sheet.
While revenue guidance for the full year hasn't been provided by Futura, the Liberum analysts are confident in their projection of £3mln, a number it sees as a reasonable starting point given Eroxon's clear market momentum.
The launch of Eroxon in other territories, such as the Middle East in the second half of 2023, further supports this optimistic forecast, the broker said.
The biotech firm's strong financial performance is even more impressive considering the uncertainties surrounding future revenue, particularly in relation to the timing of product launches and the terms of Futura's US partnership.
Liberum's valuation for Futura Medical remains unchanged at 142p per share, even after the firm's optimistic revenue forecast. The stock is currently changing hands for 59.36p.
Futura was slated to host a capital markets day to provide further insights on initial market feedback.
The presentations were to cover various topics, including feedback on initial launches in Belgium and the UK.
While future visibility beyond 2024 remains low, the company's initial success with Eroxon positions it favourably for sustained growth in the healthcare and pharmaceutical industry, the Liberum analysts concluded.